Zydus生命科学公司为141万美元购置了两家美国生物实验室设施,用于扩大癌症药物制造。 Zydus Lifesciences acquires two U.S. biologics facilities for $141M to expand cancer drug manufacturing.

印度制药公司Zydus LifeSciences正在从加利福尼亚的Agenus公司购买两个生物设施,从而进入全球生物制造市场。 Zydus Lifesciences, an Indian pharmaceutical company, is entering the global biologics manufacturing market by acquiring two biologics facilities from Agenus Inc. in California. 这一1.41亿美元的交易将使Zydus能够制造Agenus的癌症治疗,并扩大其在美国这个生物技术创新中心的存在。 This $141 million deal will allow Zydus to manufacture Agenus' cancer treatments and expand its presence in the U.S., a hub for biotech innovation. 预计到2034年全球生物市场将达到849亿美元,为Zydus带来重大增长机会。 The global biologics market is expected to reach $84.9 billion by 2034, offering significant growth opportunities for Zydus.